CN114173789A - 用于治疗由生殖支原体引起的感染的组合 - Google Patents

用于治疗由生殖支原体引起的感染的组合 Download PDF

Info

Publication number
CN114173789A
CN114173789A CN202080049062.5A CN202080049062A CN114173789A CN 114173789 A CN114173789 A CN 114173789A CN 202080049062 A CN202080049062 A CN 202080049062A CN 114173789 A CN114173789 A CN 114173789A
Authority
CN
China
Prior art keywords
gepotidacin
doxycycline
pharmaceutically acceptable
acceptable salt
mycoplasma genitalium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080049062.5A
Other languages
English (en)
Chinese (zh)
Inventor
N·斯坎加雷拉-奥曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CN114173789A publication Critical patent/CN114173789A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080049062.5A 2019-07-05 2020-07-03 用于治疗由生殖支原体引起的感染的组合 Pending CN114173789A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962870990P 2019-07-05 2019-07-05
US62/870,990 2019-07-05
US202062985465P 2020-03-05 2020-03-05
US62/985,465 2020-03-05
PCT/EP2020/068754 WO2021004910A1 (en) 2019-07-05 2020-07-03 Combination for the treatment of infections caused by mycoplasma genitalium

Publications (1)

Publication Number Publication Date
CN114173789A true CN114173789A (zh) 2022-03-11

Family

ID=71579551

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080049062.5A Pending CN114173789A (zh) 2019-07-05 2020-07-03 用于治疗由生殖支原体引起的感染的组合

Country Status (8)

Country Link
US (1) US20220257615A1 (https=)
EP (1) EP3993796B1 (https=)
JP (1) JP7638263B2 (https=)
CN (1) CN114173789A (https=)
BR (1) BR112021024845A2 (https=)
CA (1) CA3143619A1 (https=)
ES (1) ES2981617T3 (https=)
WO (1) WO2021004910A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11917094B2 (en) * 2021-02-01 2024-02-27 Aptiv Technologies Limited Automatic control of smartphone driver mode using ultra-wideband communication
EP4288035A1 (en) * 2021-02-05 2023-12-13 GlaxoSmithKline Intellectual Property Development Limited Oral solid dose formulations
JP2025532252A (ja) 2022-09-26 2025-09-29 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 処置方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106659717A (zh) * 2014-08-22 2017-05-10 葛兰素史密斯克莱知识产权发展有限公司 用于治疗淋病奈瑟球菌感染的三环含氮化合物
WO2018195098A1 (en) * 2017-04-17 2018-10-25 Ohio State Innovation Foundation Type ii topoisomerase inhibitors and methods of making and using thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008240764C1 (en) * 2007-04-20 2011-10-20 Glaxo Group Limited Tricyclic nitrogen containing compounds as antibacterial agents
US9993469B2 (en) 2013-05-28 2018-06-12 Morphochem Aktiengesellschaft Für Kombinatorishe Chemie Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106659717A (zh) * 2014-08-22 2017-05-10 葛兰素史密斯克莱知识产权发展有限公司 用于治疗淋病奈瑟球菌感染的三环含氮化合物
WO2018195098A1 (en) * 2017-04-17 2018-10-25 Ohio State Innovation Foundation Type ii topoisomerase inhibitors and methods of making and using thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CATRIONA S. BRADSHAW，等: "New Horizons in Mycoplasma genitalium Treatment", THE JOURNAL OF INFECTIOUS DISEASES, vol. 216, 15 July 2017 (2017-07-15), pages 413 *
JENSEN JØRGEN SKOV: "Mycoplasma genitalium: yet another challenging STI", THE LANCET INFECTIOUS DISEASES, vol. 17, no. 08, 9 July 2017 (2017-07-09), pages 795 - 796, XP085137636, DOI: 10.1016/S1473-3099(17)30364-X *
JØRGEN JENSEN: "In vitro evaluation of gepotidacin, an oral antimicrobial against multidrug-resistant mycoplasma genitalium", SEXUALLY TRANSMITTED INFECTIONS, vol. 95, 14 July 2019 (2019-07-14), pages 292 *
JØRGEN SKOV JENSEN，等: "In vitro activity of the first-in-class triazaacenaphthylene gepotidacin alone and in combination with doxycycline against drug-resistant and -susceptible Mycoplasma genitalium", EMERGING MICROBES & INFECTIONS, vol. 09, no. 01, 18 June 2020 (2020-06-18), pages 1388 - 1392 *

Also Published As

Publication number Publication date
BR112021024845A2 (pt) 2022-01-18
JP2022539583A (ja) 2022-09-12
JP7638263B2 (ja) 2025-03-03
EP3993796C0 (en) 2024-02-21
ES2981617T3 (es) 2024-10-09
CA3143619A1 (en) 2021-01-14
WO2021004910A1 (en) 2021-01-14
US20220257615A1 (en) 2022-08-18
EP3993796A1 (en) 2022-05-11
EP3993796B1 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
CN103732212B (zh) 包含利福昔明的药物组合物、其制备方法及其在治疗阴道感染中的应用
Leophonte et al. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin
CN114173789A (zh) 用于治疗由生殖支原体引起的感染的组合
JP2025084772A (ja) 細菌性尿路感染症の治療に使用するためのゲポチダシン
Tomioka et al. Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex
Thakare et al. Lascufloxacin hydrochloride to treat bacterial infection
EP1223935A1 (en) Methods of use of fluoroquinolone compounds against bacteria
JP2025131626A (ja) ゲポチダシンを用いて淋菌感染症を治療するためのレジメン
US7595328B2 (en) Methods of use of quinolone compounds against pneumococcal and Haemophilus bacteria
Stein et al. Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens
CN117122595A (zh) 吡啶衍生物的用途
US20250099535A1 (en) Gepotidacin and vancomycin for use in the treatment of an infection caused by staphylococcus saprophyticus
US20240108620A1 (en) Treatment Regimen
EP1242079A4 (en) Methods of anti-bacterial use of fluoroquinolonic compounds
US20220184071A1 (en) Gepotidacin for use in the treatment of bacterial urinary tract infections
CA2897758A1 (en) Rifaximin for use in the treating of vaginal infections
Dowzicky et al. Comparison of the in vitro activity of and pathogen responses to sparfloxacin with those of other agents in the treatment of respiratory tract, urinary tract, and skin and skin-structure infections
JP2006522060A5 (https=)
CN110141569A (zh) 抗牛多杀性巴氏杆菌的药物组合物
Finch A review of worldwide experience with sparfloxacin in the treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis
CN110801455A (zh) 用于治疗mrsa的药物组合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: Britain

Address after: Steve Niki

Applicant after: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT Ltd.

Address before: The Middlesex County

Applicant before: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT Ltd.

Country or region before: Britain